Tau genotype frequency in neuropathologically confirmed corticobasal degeneration (CBD) cases and controls
| Genotype | CBD, n = 57 All cases | CBD, n = 30 USA | CBD, n = 14 Canada | CBD, n = 13 UK | Controls, n = 220 All controls | Controls, n = 145 USA | Controls, n = 75 UK | PSP, n = 64 |
|---|---|---|---|---|---|---|---|---|
| Values expressed as percent (number). Controls are age-matched. Chi-square analysis shows that a highly significant increase in H1/H1 frequency occurs in all CBD cases and in CBD cases analyzed by country of origin compared with their respective controls. The significance values derived from chi-square are as follows: combined CBD (p = 0.00016, 2 df), USA CBD (p = 0.00019, 2 df), Canadian CBD (p = 0.00035, 2 df), and UK CBD (p = 0.00025, 2 df). Chi-square analysis shows that H1/H1 frequency was not different from that of PSP; p = 0.35 (1 df). | ||||||||
| PSP = progressive supranuclear palsy; n = number of individuals. | ||||||||
| H1/H1 | 84.2 (48) | 86.7 (26) | 85.7 (12) | 77 (10) | 59.6 (131) | 62.8 (91) | 53 (40) | 87.5 (56) |
| H1/H2 | 15.8 (9) | 13.3 (4) | 14.3 (2) | 23 (3) | 33.6 (74) | 31.0 (45) | 39 (29) | 12.5 (8) |
| H2/H2 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 6.8 (15) | 6.2 (9) | 8 (6) | 0 (0) |